Saturday, September 04, 2021 8:55:24 AM
WASHINGTON — The Biden administration on Friday unveiled a sweeping new biosecurity plan, outlining a $65 billion proposal to remake the nation’s pandemic preparedness infrastructure in the wake of Covid-19.
The new spending would represent one of the largest investments in public health in American history: During a press briefing, Eric Lander, the White House science adviser, likened the proposal to the Apollo program of the late 1960s.
The immense funding boost would target programs aimed at developing and manufacturing vaccines, treatments, and tests more quickly. It would also provide new money for laboratory capacity, viral detection mechanisms, and early warning systems.
“For the first time in the nation’s history, due to these types of advancements in scientific technology, we have the opportunity not just to refill stockpiles but to transform our capabilities,” Lander said. “But we really need to start preparing now.”
Indeed, the White House funding request comes with a near-term deadline. While the spending would be spread over the coming seven to 10 years, it also includes an ask for at least $15 billion to be included within a forthcoming, $3.5 trillion budget plan still pending on Capitol Hill. The White House is still in discussions with Congress, Lander said, but he was “very optimistic” that lawmakers would agree to the request.
The new spending would target a wide array of new pandemic preparedness capabilities. It would include over $24 billion for vaccine infrastructure, with a goal of beginning to manufacture vaccine doses meant to protect against any virus family within 100 days of a pandemic threat first emerging.
The plan would include nearly $12 billion to develop — and have on hand — a range of treatments available for any known virus family even before a particular pathogen emerged as a pandemic threat.
It would also provide $5 billion for diagnostics that the government would aim to make available within weeks of identifying a new biosecurity threat.
“What this plan is about is ensuring the United States has the capabilities it needs to operationalize [its response] when we see the first signs of an emerging outbreak that could have epidemic or pandemic potential,” Beth Cameron, the top biosecurity expert on the National Security Council, said during the briefing.
It’s not yet clear how Congress will respond to the Biden administration’s sweeping proposal, which expands on a previous request to spend $30 billion over four years on improving future pandemic prevention and preparedness. In a subsequent version of Democrats’ budget bill, however, lawmakers included just $5 billion, drawing criticism from many public health experts who said the government was repeating the same mistakes that led to the country’s chaotic response to Covid-19.
The $65 billion proposal doesn’t stop at treatments, tests, and vaccines.
It would include $3.1 billion aimed at establishing an early-warning system for new disease outbreaks, including systems to sequence pathogens found in wastewater and a “reliable clinical surveillance system.” Biden also calls for spending to help reduce health inequity, fund lab capacity, and improve public health communication. He also wants to put money toward developing better protective equipment for health workers and creating better systems for “pathogen protection,” like better ventilation systems and surface cleaners.
The plan also includes measures to ensure that research and development “involving potentially dangerous biological agents is conducted safely and securely, by fostering a global research environment that adopts and enforces high standards.” The lab-safety provisions are a potential nod to the unproven theory that Covid-19 originated from “gain-of-function” research performed in a Chinese laboratory, a long-running controversy in U.S. and global politics.
https://www.statnews.com/2021/09/03/biden-wants-65-billion-for-apollo-style-pandemic-preparedness-program/
https://www.whitehouse.gov/wp-content/uploads/2021/09/American-Pandemic-Preparedness-Transforming-Our-Capabilities-Final-For-Web.pdf
Recent INO News
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/01/2024 12:00:00 PM
- INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO to Participate in Upcoming Investor Conferences in May • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM